Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1587-1593, 2005. First published July 14, 2005; 10.1373/clinchem.2005.047845
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.047845v1
51/9/1587    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McHugh, C. M.
Right arrow Articles by Holt, R. I.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McHugh, C. M.
Right arrow Articles by Holt, R. I.G.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:1587-1593.)
© 2005 American Association for Clinical Chemistry, Inc.

Reviews

Challenges in Detecting the Abuse of Growth Hormone in Sport

Cathy M. McHugha,1, Roderick T. Park1, Peter H. Sönksen1 and Richard I.G. Holt1

1 Endocrinology & Metabolism Sub-Division, Developmental Origins of Adult Health and Disease Division, School of Medicine, University of Southampton, Southampton, United Kingdom.

aAddress correspondence to this author at: Level F (MP113) Centre Block, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. Fax 44-23-8079-4945; e-mail cathy.mchugh{at}soton.ac.uk.

Background: Growth hormone (GH) is reputed to be in widespread use in the sporting arena as a performance-enhancing agent and is on the list of banned substances published by the World Anti-Doping Agency. The detection of GH abuse poses many challenges. Unlike many substances of abuse, such as synthetic anabolic steroids, GH is a naturally occurring substance; therefore, demonstration of exogenous administration must rely on detecting concentrations in excess of an established reference interval. The purpose of this review is to discuss the methodologies being developed to detect GH abuse.

Methods: We undertook a comprehensive search using multiple electronic databases and hand searches of reference lists of articles. The data for this review reflect our academic interests and experience through work on the GH-2000 and GH-2004 projects.

Results: Two approaches have been taken to detect GH abuse. The first is based on assessment of the effect of exogenous GH on pituitary GH isoforms, and the second is based on measurement of markers of GH action. The advantages of each approach and the difficulties encountered with each technique, as well as future concepts in detection, are discussed.

Conclusion: Although there are substantial challenges for the detection of GH, methodologies now exist to detect GH abuse with reasonable sensitivity and specificity.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin, E. J. He, M. Kawakubo, E. T. Schroeder, K. Yarasheski, G. J. Opiteck, A. Reicin, F. Chen, R. Lam, J. A. Tsou, et al.
N-Terminal Propeptide of Type III Procollagen as a Biomarker of Anabolic Response to Recombinant Human GH and Testosterone
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4224 - 4233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Bidlingmaier, J. Suhr, A. Ernst, Z. Wu, A. Keller, C. J. Strasburger, and A. Bergmann
High-Sensitivity Chemiluminescence Immunoassays for Detection of Growth Hormone Doping in Sports
Clin. Chem., March 1, 2009; 55(3): 445 - 453.
[Abstract] [Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
J. Young and A. Anwar
Strong diabetes
BMJ Case Reports, February 2, 2009; 2009(jan27_1): bcr0820080708 - bcr0820080708.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
G. Lippi, F. Schena, M. Montagnana, G. L. Salvagno, G. Banfi, and G. C. Guidi
Acute Variation of Osteocalcin and Parathyroid Hormone in Athletes after Running a Half-Marathon
Clin. Chem., June 1, 2008; 54(6): 1093 - 1095.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Gibney, M.-L. Healy, and P. H. Sonksen
The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport
Endocr. Rev., October 1, 2007; 28(6): 603 - 624.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Sports. Med.Home page
J. Young, A. Anwar, and C. Milne
Strong diabetes * COMMENTARY
Br. J. Sports Med., May 1, 2007; 41(5): 335 - 336.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.